ETV5 and ovarian carcinoma: We verified increased expression of Etv4 and Etv5 in MOSE-HRAS cells (Fig. 6b), suggesting that this model recapitulated the differences we observed in CCNE1 and RTK/RAS-driven ovarian cancers.